profit from every €100 of sales.
€0€100
Lakefront Biotherapeutics NV
€30.14-2.77% today
+8.0% since Dec 21, 25
1-year low €22.881-year high €31.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €6.19 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Lakefront Biotherapeutics NV sold, what it kept, and what it did with the cash.
Sales went from €241 million in 2022 to €1.11 billion in 2025, with €321 million of profit last year.
SalesProfit
Lakefront Biotherapeutics NV vs. similar companies
Lakefront Biotherapeutics NV grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Lakefront Biotherapeutics NV | 6.2× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Lakefront Biotherapeutics NV's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 241 | 240 | 276 | 1,112 | |
| 241 | 240 | 241 | 1,083 | |
| -131 | -88 | -188 | 501 | |
| 4 | 51 | 43 | 359 | |
| -218 | 212 | 74 | 321 | |
| -3.32 | 3.21 | 1.12 | 4.87 | |
| 100.0% | 100.0% | 87.4% | 97.3% | |
| -54.3% | -36.8% | -68.3% | 45.1% | |
| -90.4% | 88.3% | 26.9% | 28.9% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,734 | 4,357 | 4,136 | 3,407 |
| Cash | 508 | 167 | 64 | 88 |
| Total debt | 22 | 10 | 12 | 7 |
| Total liabilities | 2,208 | 1,562 | 1,239 | 171 |
| 2,526 | 2,796 | 2,897 | 3,236 | |
| 66 | 66 | 66 | 66 | |
| -1.7% | 0.2% | -0.1% | 6.5% | |
| -8.6% | 7.6% | 2.6% | 9.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -501 | -406 | -320 | -257 | |
| 37 | 19 | 82 | 14 | |
| -537 | -425 | -402 | -271 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 89 | 57 | 20 | 24 |
Valuation
- 6.2×
- –
- –
- 0.5×
- 1.8×
- –
- 5.3×
- -13.7%
- 16.2%
- –
Profitability
- 97.3%
- 45.1%
- 28.9%
- –
- 6.5%
- 1.2%
- –
- –
- –
- –
Growth
- +66.4%
- –
- –
- –
- +0.1%
Financial health
- -0.2×
- 0.00
- –
- 136.7×
- 20.15
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 952
Top 3%of 883
Top 4%of 601
Top 9%of 888
Bottom 7%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
91Pass
Philip Fisher
77Pass
Peter Lynch
100Pass
Joel Greenblatt
65Pass
Charlie Munger
63Pass
Terry Smith
56No pass
Questions about Lakefront Biotherapeutics NV
Is Lakefront Biotherapeutics NV a good stock to buy?
A strong, very profitable business, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lakefront Biotherapeutics NV AI analysis
What does Lakefront Biotherapeutics NV do?
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. It is in Biotechnology, based in Mechelen, Belgium.
Is Lakefront Biotherapeutics NV stock halal?
No. Lakefront Biotherapeutics NV does not pass our halal screen: its cash and confirmed interest-bearing investments are 77% of its market value, at or above the 33% limit. How we check
Who are Lakefront Biotherapeutics NV's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Lakefront Biotherapeutics NV's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.